Table 3.
Differences in changes of plasma levels of fatty acids between the surgery-group (7–59 weeks) and the lifestyle-group (baseline-59 weeks) of trial 1a
| Mean difference (95% CI) | P† | |
|---|---|---|
| SFAs, % of total fatty acids | ||
| Total SFA | 0.44 (-0.01, 0.89) | 0.06 |
| Myristic acid, 14:0 | 0.31 (0.21, 0.42) | < 0.001 |
| Pentadecylic acid, 15:0 | 0.04 (0.02, 0.06) | < 0.001 |
| Palmitic acid, 16:0 | -0.62 (-1.07, -0.18) | 0.006 |
| Stearic acid, C18:0 | 0.75 (0.51, 0.99) | < 0.001 |
| MUFAs, % of total fatty acids | ||
| Total MUFA | 0.14 (-0.73, 1.02) | 0.75 |
| Palmitoleic acid, 16:1 n-7 | -0.05 (-0.23, 0.12) | 0.53 |
| Oleic acid, 18:1 n-9 | 0.39 (-0.34, 1.13) | 0.29 |
| Vaccenic acid, 18:1 n-7 cis | -0.18 (-0.26, -0.10) | < 0.001 |
| Eicosenoic acid, 20:1 n-9 | 0.00 (0.00, 0.00) | 1.00 |
| n-6 PUFAs, % of total fatty acids | ||
| Total n-6 PUFAs | -0.28 (-1.48, 0.92) | 0.65 |
| LA, C18:2 n-6 | 0.76 (-0.33, 1.85) | 0.17 |
| GLA, C18:3 n-6 | 0.09 (0.04, 0.13) | < 0.001 |
| EDA, C20:2 n-6 | 0.05 (0.03, 0.06) | < 0.001 |
| DGLA, C20:3 n-6 | 0.27 (0.15, 0.38) | < 0.001 |
| AA, C20:4 n-6 | -1.15 (-1.55, -0.76) | < 0.001 |
| n-3 PUFAs, % of total fatty acids | ||
| Total n-3 PUFAs | -0.98 (-1.44, -0.52) | < 0.001 |
| ALA, C18:3 n-3 | 0.10 (0.05, 0.15) | < 0.001 |
| EPA, C20:5 n-3 | -0.32 (-0.54, -0.10) | 0.005 |
| DPA, C22:5 n-3 | 0.04 (0.00, 0.08) | 0.042 |
| DHA, C22:6 n-3 | -0.70 (-0.91, -0.48) | < 0.001 |
Abbreviations: AA arachidonic acid, ALA alpha linolenic acid, DGLA dihomo-gamma-linolenic acid, DHA docosahexaenoic acid, DPA docosapentaenoic, EDA eicosadienoic acid, EPA eicosapentaenoic acid, GLA gamma-linolenic acid, LA linoleic acid, MUFA monounsaturated fatty acids, SFA saturated fatty acids, PUFA polyunsaturated fatty acids
aCalculated using robust linear regression
†Adjusted for age, sex and weight change